The justification for a surgical staging system in endometrial carcinoma
- PMID: 8255995
- DOI: 10.1016/0167-8140(93)90057-f
The justification for a surgical staging system in endometrial carcinoma
Abstract
Three hundred and one patients with endometrial carcinoma who were surgically staged and treated postoperatively with irradiation at the Fox Chase Cancer Center or the Hospital of the University of Pennsylvania were retrospectively substaged by the 1988 FIGO staging system. For pathological stage I endometrial carcinoma, FIGO substage (IA/IB vs. IC) in addition to depth by thirds (< or = 2/3 vs. > 2/3), grade (1 or 2 vs. 3), age (< or = 60 vs. > 60), and type of postoperative irradiation (vaginal alone vs. external +/- vaginal) were predictive for 5-year cause-specific survival in univariate analysis. For all pathological stages, excluding IIIB and IV endometrial carcinoma, FIGO stage (I or II vs. III) in addition to depth by thirds (< or = 2/3 vs. > 2/3), grade (1 or 2 vs. 3), age (< or = 60 vs. > 60), and type of postoperative irradiation (vaginal alone vs. external +/- vaginal) were predictive for 5-year cause-specific survival in univariate analysis. Clinical stage (I vs. II or III) was not a significant predictor of outcome in univariate analysis. Multivariate analysis of the above factors revealed FIGO stage in addition to grade, age and depth by thirds to be independent predictors of outcome. In conclusion, the FIGO surgical staging system better predicts outcome compared with the prior clinical staging system, although the FIGO substaging needs refinement. Grade, age, and depth by thirds are equally important prognostic factors in addition to FIGO stage and can add to the predictive value of the current FIGO staging system.
Similar articles
-
The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.Gynecol Oncol. 2006 Oct;103(1):87-93. doi: 10.1016/j.ygyno.2006.01.038. Epub 2006 Mar 20. Gynecol Oncol. 2006. PMID: 16545441
-
Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):81-97. doi: 10.1016/s0360-3016(00)01571-6. Int J Radiat Oncol Biol Phys. 2001. PMID: 11316550 Clinical Trial.
-
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.Gynecol Oncol. 2000 Apr;77(1):55-65. doi: 10.1006/gyno.2000.5737. Gynecol Oncol. 2000. PMID: 10739691
-
Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy.Gynecol Oncol. 1999 Oct;75(1):103-7. doi: 10.1006/gyno.1999.5526. Gynecol Oncol. 1999. PMID: 10502434 Review.
-
Staging for endometrial carcinoma FIGO 2023 and its relevance for clinical practice.Klin Onkol. 2024;37(4):250-258. doi: 10.48095/ccko2024250. Klin Onkol. 2024. PMID: 39174328 Review. English.
Cited by
-
Partial silencing of fucosyltransferase 8 gene expression inhibits proliferation of Ishikawa cells, a cell line of endometrial cancer.Biochem Biophys Rep. 2020 Feb 12;22:100740. doi: 10.1016/j.bbrep.2020.100740. eCollection 2020 Jul. Biochem Biophys Rep. 2020. PMID: 32099910 Free PMC article.
-
Global Trends in Incidence and Mortality Rates of Endometrial Cancer Among Individuals Aged 55 years and Above From 1990 to 2021: An Analysis of the Global Burden of Disease.Int J Womens Health. 2025 Mar 6;17:651-662. doi: 10.2147/IJWH.S499435. eCollection 2025. Int J Womens Health. 2025. PMID: 40066179 Free PMC article.
-
Hematogenous metastases in patients with Stage I or II endometrial carcinoma.Strahlenther Onkol. 2011 Dec;187(12):806-11. doi: 10.1007/s00066-011-2250-6. Epub 2011 Nov 17. Strahlenther Onkol. 2011. PMID: 22105770
MeSH terms
LinkOut - more resources
Full Text Sources